Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Income Statement
- Analysis of Short-term (Operating) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2012
- Return on Assets (ROA) since 2012
- Debt to Equity since 2012
- Price to Earnings (P/E) since 2012
- Price to Book Value (P/BV) since 2012
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
- Debt to Equity Ratio
- The ratio exhibited a downward trend from 6.24 in the first quarter of 2021 to 3.67 by the end of 2022, indicating a reduction in debt relative to equity. However, starting in 2023, the ratio increased markedly, reaching 20.19 by the end of 2024 and further rising to 49.22 by mid-2025, signaling a substantial increase in leverage and possibly greater reliance on debt financing.
- Debt to Capital Ratio
- This ratio displayed relative stability with minor fluctuations around 0.8 to 0.9 from 2021 through 2023. Beginning in early 2024, the ratio showed an upward trend, reaching 0.95 by late 2024 and further increasing to 1.04 by mid-2025. Values above 1.0 suggest that total debt may have exceeded total capital, which is an unusual and potentially concerning indication of financial structure.
- Debt to Assets Ratio
- The debt to assets ratio gradually decreased from 0.57 in early 2021 to about 0.44 by the end of 2023, indicating a reduction in the proportion of assets financed by debt during this period. From 2024 onwards, the ratio stabilized around 0.50 to 0.51, reflecting consistent asset financing structure with around half of assets funded by debt.
- Financial Leverage Ratio
- This ratio followed a similar pattern to debt to equity, declining from 10.98 in early 2021 to a low of 8.04 at the end of 2022. Thereafter, it increased substantially reaching 13.0 by late 2023 and surged dramatically to 95.89 by mid-2025. This sharp rise signals a significant increase in leverage, indicating that the company’s assets are being supported by a much higher level of liabilities relative to shareholders’ equity.
- Overall Analysis
- Between 2021 and 2022, the company showed a trend toward reduced leverage and improved capital structure, with decreasing debt-related ratios suggesting stronger equity or asset bases relative to debt. However, starting in 2023, all leverage indicators suggest a pronounced increase in indebtedness, particularly notable with steep increases in financial leverage and debt to equity. By mid-2025, the financial metrics reflect aggressive use of debt financing, which could raise concerns about financial risk and solvency if such trends are not managed prudently.
Debt Ratios
Debt to Equity
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||||
| Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||||||
| Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial trends over the reported quarters reveals significant fluctuations in both the total debt and stockholders’ equity, impacting the overall debt to equity ratio.
- Total Debt
-
The total debt exhibited a general downward trend from the first quarter of 2021 through the end of 2023, declining from approximately $85.5 billion to around $59.4 billion. This reduction suggests concerted efforts to lower leverage during this period. However, starting in early 2024, total debt increased again, rising to about $74.0 billion by the first quarter of 2024, followed by some fluctuations with values mostly remaining above $67 billion up to late 2025. This reversal indicates renewed borrowing or issuance of debt towards the latter periods.
- Stockholders’ Equity
-
Stockholders’ equity initially showed moderate growth from about $13.7 billion in early 2021 to a peak of approximately $17.3 billion by the end of 2022. After this peak, a pronounced decline followed, falling sharply through 2023 and continuing into 2025, ultimately reaching negative values near -$2.6 billion by the third quarter of 2025. This significant erosion of equity could be indicative of sustained losses, share buybacks, dividend payments outpacing earnings, or other equity-reducing transactions.
- Debt to Equity Ratio
-
The debt to equity ratio reflects these movements markedly. Initially, the ratio hovered between approximately 4.5 and 6.5, indicating relatively stable leverage with some moderate variability. Toward the end of 2023 and into 2024, the ratio increased dramatically, reaching as high as 20.2 and even 49.2 in some periods in 2025, before data becomes unavailable. This sharp increase corresponds to the combination of rising total debt and sharply declining or negative equity, signaling a substantial increase in financial risk and leverage.
Overall, the company’s financial structure tightened significantly over the analyzed quarters. Initially, efforts appeared focused on reducing total debt and maintaining or increasing equity. However, starting in 2024, the trends reversed, with debt rising and equity declining substantially, resulting in elevated leverage levels. This development suggests increased financial risk and necessitates further scrutiny into the underlying causes and potential impacts on the company’s creditworthiness and financial stability.
Debt to Capital
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||||
| Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||||||
| Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends in debt management and capital structure over the observed quarterly periods. Total debt exhibited an overall declining trajectory from the beginning until the end of 2023, decreasing from approximately $85.5 billion to about $59.4 billion. However, starting in early 2024, a reversal in this downward trend is evident as total debt rises again, reaching close to $68.7 billion by the third quarter of 2025.
Total capital similarly follows a decreasing pattern initially, dropping from roughly $99.2 billion in the first quarter of 2021 to around $69.7 billion at the close of 2023. A subsequent modest increase occurs in early 2024, with total capital peaking near $82.0 billion, but this is followed again by a gradual decline to approximately $66.1 billion by the third quarter of 2025.
The debt-to-capital ratio provides insight into the leverage dynamics throughout the period. From early 2021 to the end of 2023, the ratio trends downward from 0.86 to a low of 0.79, implying a reduction in leverage and an improved balance between debt and total capital. From 2024 onward, the ratio increases steadily, exceeding 1.00 by the third quarter of 2025, which signifies that total debt has surpassed total capital. This rising leverage ratio suggests increased financial risk and greater reliance on debt financing during this latter period.
- Total Debt
- Shows a general decrease through 2021 to 2023, followed by a significant increase from 2024 to 2025.
- Total Capital
- Initially declines steadily, with a brief increase in early 2024, then resumes a downward trend through 2025.
- Debt-to-Capital Ratio
- Declines initially, reaching a minimum below 0.80 at the end of 2023, before rising sharply above 1.00 by late 2025, indicating growing leverage.
Overall, the patterns suggest a period of deleveraging until late 2023, followed by increased borrowing and a heightened debt burden relative to capital in the ensuing periods. This evolving capital structure could affect the company’s financial flexibility and risk profile.
Debt to Assets
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||||
| Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||||||
| Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- Over the observed periods, total debt demonstrates a general downward trend from March 2021 through December 2023, declining from approximately $85.5 billion to about $59.4 billion. This reduction indicates an effort in deleveraging or debt repayment. However, starting from March 2024, total debt increases again, rising to around $74.0 billion and remaining elevated through September 2025 with figures fluctuating roughly between $67.1 billion and $70.5 billion. This recent upward movement suggests renewed borrowing or acquisition-related financing activities.
- Total Assets
- Total assets show a gradual decrease from about $150.5 billion at the beginning of the period (March 2021) to approximately $134.7 billion by December 2023, indicating a possible contraction or asset divestiture over this timeframe. Notably, from March 2024 onward, total assets rebound to near $148.9 billion in March 2024, before experiencing some variability and a moderate decline again by September 2025 to around $133.9 billion. The fluctuation in asset values suggests changes in asset composition or strategic asset management occurring throughout the analyzed period.
- Debt to Assets Ratio
- The debt to assets ratio follows a declining pattern from 0.57 in March 2021 to a low of 0.44 in December 2023, reflecting a strengthening balance sheet with relatively less reliance on debt financing against total assets. Starting in March 2024, the ratio increases to the 0.50-0.51 range and remains relatively stable at that elevated level through September 2025. This shift indicates a greater proportion of debt relative to assets during the later period, despite the earlier improvement, signaling a change in capital structure strategy or increased indebtedness.
- Overall Financial Trends
- The financial data reveals two distinct phases over the analyzed intervals. The initial phase, up to late 2023, is characterized by consistent debt reduction, shrinking asset base, and improvement in the debt to assets ratio. The latter phase, commencing early 2024, shows a reversal with rising debt levels, growing assets, and a consequent increase in leverage ratios. These trends may reflect shifting corporate priorities, such as capital raising for investment or acquisition purposes, or adjustments in financial policy responding to market conditions.
Financial Leverage
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data over the observed periods reveals several noteworthy trends in asset management, equity position, and financial leverage ratios.
- Total Assets
- The total assets exhibit a gradual decreasing trend from the initial period to the end of 2023, declining from approximately $150.5 billion to around $134.7 billion. However, in 2024, there is an increase in total assets with a peak near $148.9 billion in the first quarter, followed by a decrease through to early 2025, settling near $133.9 billion by the third quarter of 2025. This pattern indicates some volatility and possible strategic activity affecting asset levels during these years.
- Stockholders’ Equity
- Stockholders' equity demonstrates a declining trajectory over the timeframe. Initially, equity was positive, rising to a maximum of about $17.3 billion in late 2022, but then showing a steady decrease starting in 2023. By the first quarter of 2024, equity had sharply dropped to around $8.0 billion, continuing its downward trend into negative territory by mid-2025, reaching a deficit of approximately $2.6 billion. This significant decline in equity levels and eventual equity deficit may reflect increasing liabilities, losses, or changes in capital structure.
- Financial Leverage
- The financial leverage ratio shows considerable fluctuation. Initially high at around 11, it decreased to approximately 8 by the end of 2021, indicating a reduction in leverage. However, from early 2023 onwards, the ratio started to rise dramatically, peaking at 40.65 in late 2024, and escalating further to 95.89 by mid-2025 (noting that the last two periods do not have data). This sharp increase signifies a substantial increase in debt relative to equity, consistent with the observed drop in stockholders' equity. Such a leverage spike usually points to heightened financial risk and dependence on external financing.
In summary, the data highlights a trend of declining equity alongside an initially stable but later increasing leverage, suggesting increasing financial risk and potentially aggressive financing strategies or operational challenges. Total assets have shown some degree of fluctuation with a temporary rebound; however, the downward pressure on equity and the surge in leverage warrant close monitoring. These patterns may impact investor confidence and the company’s financial stability going forward.